Shifting landscape of hemophilia therapy: Implications for current clinical laboratory coagulation assays

American Journal of Hematology

Volumn 93, Issue 8, 2018, Pages 1082-1090

  Al Samkari, Hanny ^a,b   Croteau, Stacy E ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; EMICIZUMAB; THROMBIN; VON WILLEBRAND FACTOR;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ASSAY; BLOOD CLOTTING TEST; CHROMOGENIC SUBSTRATE ASSAY; CLINICAL DECISION MAKING; COAGULATION ASSAY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; HEMOPHILIA; HEMOSTASIS; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; ONE STAGE CLOTTING ASSAY; POINT MUTATION; PRIORITY JOURNAL; REVIEW; TWO STAGE CLOTTING ASSAY;

EID: 85051742098     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.25153     Document Type: Review

References (73)

1. Peters RT, Toby G, Lu Q, et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost. 2013;11(1):132–141.
2. Turecek PL, Bossard MJ, Graninger M, et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie. 2012;32(S 01):S29–S38.
3. Morfini M. Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia. Expert Opin Drug Metab Toxicol. 2016;12(11):1359–1365.
4. Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313–2323.
5. Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011;118(10):2695–2701.
6. Scott LJ, Kim ES. Emicizumab-kxwh: first global approval. Drugs. 2018;78(2):269–274.
7. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809–818.
8. Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743–754.
9. Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in Hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377(9):819–828.
10. Gale AJ, Bhat V, Pellequer JL, et al. Safety, stability and pharmacokinetic properties of (super)Factor Va, a novel engineered coagulation Factor V for treatment of severe bleeding. Pharm Res. 2016;33(6):1517–1526.
11. Barrowcliffe TW. Factor VIII and thrombin generation assays: relevance to pharmacokinetic studies in haemophilia A. Haemophilia. 2006;12(s4):23–29.
12. Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hamostaseologie. 2010;30(04):207–211.
13. Hubbard AR, Sands D, Sandberg E, et al. A multi-centre collaborative study on the potency estimation of ReFacto. Thromb Haemost. 2003;90(6):1088–1093.
14. Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016;14(2):248–261.
15. Chitlur M, Young G. Global assays in hemophilia. Semin Hematol. 2016;53(1):40–45.
16. Hemlibra (emicizumab-kxwh). Package insert. Genentech, Inc, South San Francisco, CA; 2017.
17. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.
18. Barrowcliffe TW. Monitoring haemophilia severity and treatment: new or old laboratory tests?. Haemophilia. 2004;10(Suppl 4):109–114.
19. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost. 1991;66(3):384–386.
20. Iorio A, Blanchette V, Blatny J, et al. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. J Thromb Haemost. 2017;15(12):2461–2465.
21. Croteau SE, Callaghan MU, Davis J, et al. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018;93:1–8.
22. Potgieter JJ, Damgaard M, Hillarp A. One-stage vs. chromogenic assays in haemophilia A. Eur J Haematol. 2015;94(Suppl 77):38–44.
23. Dodt J, Hubbard AR, Wicks SJ, et al. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia. 2015;21(4):543–549.
24. National Hemophilia Foundation Medical and Science Advisory Committee Statement Regarding Use of Various Clotting Factor Assays to Monitor Factor Replacement Therapy. 2014;MASAC Document #228.
25. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. J Lab Clin Med. 1953;41:637–647.
26. Over J. Methodology of the one-stage assay of Factor VIII (VIII:C). Scand J Haematol Suppl. 1984;41:13–24.
27. Verbruggen B, Meijer P, Novakova I, et al. Diagnosis of factor VIII deficiency. Haemophilia. 2008;14(s3):76–82.
28. Mackie I, Cooper P, Lawrie A, et al. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int Jnl Lab Hem. 2013;35(1):1–13.
29. Biggs R, Eveling J, Richards G. The assay of antihaemophilic-globulin activity. Br J Haematol. 1955;1(1):20–34.
30. Seghatchian MJ, Miller-Anderson M, Howarth DJ, et al. Proceedings: Automated techniques for estimating factor VIII levels in concentrate preparations. Thromb Diath Haemorrh. 1975;34(2):611.
31. Wagenvoord RJ, Hendrix HH, Hemker HC. Development of a simple chromogenic factor VIII assay for clinical use. Pathophysiol Haemos Thromb. 1989;19(4):196–204.
32. Rosen S. Assay of factor VIII:C with a chromogenic substrate. Scand J Haematol Suppl. 1984;40:139–145.
33. Barrowcliffe TW. Standardization of FVIII & FIX assays. Haemophilia. 2003;9(4):397–402.
34. Mani H, Lindhoff-Last E. Main considerable factors for correct laboratory test interpretation under DOA treatment. Thrombosis J. 2013;11(1):22.
35. Rosen S, Andersson M, Blomback M, et al. Clinical application of a chromogenic substrate method for determination of factor VIII activity. Thromb Haemost. 1985;54(4):818–823.
36. Barrowcliffe TW, Tubbs JE, Wong MY. Evaluation of factor VIII deficient plasmas. Thromb Haemost. 1993;70(3):433–437.
37. Rothschild C, Amiral J, Adam M, et al. Preparation of factor-VIII-depleted plasma with antibodies and its use for the assay of factor VIII. Haemostasis. 1990;20(6):321–328.
38. St Ledger K, Feussner A, Kalina U, et al. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories. J Thromb Haemost. 2018;16(3):555–564.
39. Sommer JM, Moore N, McGuffie-Valentine B, et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia. 2014;20(2):294–300.
40. Kitchen S, Beckmann H, Katterle Y, et al. BAY 81–8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study. Haemophilia. 2016;22(3):e192–e199.
41. Viuff D, Barrowcliffe T, Saugstrup T, et al. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia. 2011;17(4):695–702.
42. Hillarp A, Bowyer A, Ezban M, et al. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study. Haemophilia. 2017;23(3):458–465.
43. Pouplard C, Caron C, Aillaud MF, et al. The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay. Haemophilia. 2011;17:e958–962.
44. Sommer JM, Buyue Y, Bardan S, et al. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. Thromb Haemost. 2014;112(5):932–940.
45. St. Ledger K, Fuessner A, Kalina U, Jacobs I, Voigt C, Bensen-Kennedy D. Performance of a recombinant fusion protein linking coagulation factor IX with albumin (rFIX-FP) in the one–stage assay. Haemophilia. 2016;22:60.
46. Bowyer AE, Hillarp A, Ezban M, et al. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study. J Thromb Haemost. 2016;14(7):1428–1435.
47. Sorensen MH, Andersen S, Ezban M. Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays. Haemophilia. 2015;21(6):832–836.
48. Rosen P, Rosen S, Ezban M, et al. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX. J Thromb Haemost. 2016;14(7):1420–1427.
49. Lee CA, Kessler CM, Varon D, et al. Discrepancies in potency assessment of recombinant FVIII concentrates. Haemophilia. 1998;4(4):634–640.
50. Gu JM, Ramsey P, Evans V, et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94–9027) for haemophilia A. Haemophilia. 2014;20(4):593–600.
51. Barrowcliffe TW, Watton J, Harman A, et al. Potency of high purity factor VIII concentrates. Lancet. 1990;336(8707):124.
52. Hubbard AR, Weller LJ, Bevan SA. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. Br J Haematol. 2002;117(1):247–248.
53. Rodgers SE, Duncan EM, Barbulescu DM, et al. In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results. Br J Haematol. 2007;136(1):138–145.
54. Parquet-Gernez A, Mazurier C, Goudemand M. Functional and immunological assays of FVIII in 133 haemophiliacs–characterization of a subgroup of patients with mild haemophilia A and discrepancy in 1- and 2-stage assays. Thromb Haemost. 1988;59(2):202–206.
55. Lyall H, Hill M, Westby J, et al. Tyr346–>Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A?. Haemophilia. 2007;0(0):071124115610001–071124115610080.
56. Trossaert M, Regnault V, Sigaud M, et al. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype. J Thromb Haemost. 2008;6(3):486–493.
57. Pavlova A, Delev D, Pezeshkpoor B, et al. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays. Thromb Haemost. 2014;111(05):851–861.
58. Fay PJ. Factor VIII structure and function. Int J Hematol. 2006;83(2):103–108.
59. Wang Y, Geer LY, Chappey C, et al. Cn3D: sequence and structure views for Entrez. Trends Biochem Sci. 2000;25(6):300–302.
60. Hakeos WH, Miao H, Sirachainan N, et al. Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy. Thromb Haemost. 2002;88(5):781–787.
61. Bowyer A, Key N, Dalton D, et al. The coagulation laboratory monitoring of Afstyla single-chain FVIII concentrate. Haemophilia. 2017;23(5):e469–e470.
62. Friedman KD, Powell JS, Bensen-Kennedy D. Response: The coagulation laboratory monitoring of AFSTYLA single-chain FVIII concentrate. Haemophilia. 2018;24(3):e129–131.
63. Hartmann J, Croteau SE. 2017 Clinical trials update: Innovations in hemophilia therapy. Am J Hematol. 2016;91(12):1252–1260.
64. Jimenez-Yuste V, Shima M, Fukutake K, et al. Emicizumab subcutaneous dosing every 4 weeks for the management of Hemophilia A: preliminary data from the pharmacokinetic run-in cohort of a multicenter, open-label, phase 3 Study (HAVEN. Blood. 2017;130:486
65. Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014;12(2):206–213.
66. Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in Hemophilia A. N Engl J Med. 2016;374(21):2044–2053.
67. Shima M, Hanabusa H, Taki M, et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017;1(22):1891–1899.
68. Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood. 2017;130(23):2463–2468.
69. Young G, Sorensen B, Dargaud Y, et al. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013;121(11):1944–1950.
70. Salvagno GL, Berntorp E. Thrombin Generation Assays (TGAs). Methods Mol Biol. 2017;1646:515–522.
71. Panteleev MA, Hemker HC. Global/integral assays in hemostasis diagnostics: promises, successes, problems and prospects. Thrombosis J. 2015;13(1):5.
72. Sakurai Y, Hardy ET, Ahn B, et al. A microengineered vascularized bleeding model that integrates the principal components of hemostasis. Nat Commun. 2018;9(1):509.
73. Padovani F, Duffy J, Hegner M. Nanomechanical clinical coagulation diagnostics and monitoring of therapies. Nanoscale. 2017;9(45):17939–17947.